Frontiers | Therapeutic Antibodies against Intracellular Tumor Antigens
Monoclonal antibodies are among the most clinically effective drugs used to treat cancer. However, their target repertoire is limited as there are relatively few tumor-specific or tumor-associated cell surface or soluble antigens. Intracellular molecules represent nearly half of the human proteome and provide an untapped reservoir of potential therapeutic targets. Antibodies have been developed to target externalized antigens, have also been engineered to enter into cells or may be expressed intracellularly with the aim of binding intracellular antigens. Furthermore, intracellular proteins can be degraded by the proteasome into short, commonly 8–10 amino acid long, peptides that are presented on the cell surface in the context of major histocompatibility complex class I (MHC-I) molecules. These tumor-associated peptide–MHC-I complexes can then be targeted by antibodies known as T-cell receptor mimic (TCRm) or T-cell receptor (TCR)-like antibodies, which recognize epitopes comprising both the peptide and the MHC-I molecule, similar to the recognition of such complexes by the TCR on T cells. Advances in the production of TCRm antibodies have enabled the generation of multiple TCRm antibodies, which have been tested in vitro and in vivo, expanding our understanding of their mechanisms of action and the importance of target epitope selection and expression. This review will summarize multiple approaches to targeting intracellular antigens with therapeutic antibodies, in partic...
;import{g as i,s as o,r as s,e as a,a as u,h as l,b as c,i as h,t as f,c as d,d as p,f as m,j as g,k as y,l as b,K as v,_ as w,S as E,m as _,o as C,w as M,n as S,p as O,q as B,u as D,v as I,x as T,y as x,z as R,A as N,G as k,J as F,B as L,C as P,X as U,D as j,E as q,F as z,H as $,I as V,L as H,M as W,N as G,O as K,P as Z,Q as Y,R as J,T as X,U as Q,V as AA,W as eA,Y as tA,Z as rA,$ as nA,a0 as iA,a1 as oA,a2 as sA,a3 as aA,a4 as uA,a5 as lA,a6 as cA,a7 as hA,a8 as fA,a9 as dA,aa as pA,ab as mA,ac as gA,ad as yA,ae as bA,af as vA,ag as wA,ah as EA,ai as _A,aj as CA,ak as MA,al as SA,am as OA}fr
Explore this link on the map →saved by
related reading
- Frontiers | Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Diseasefrontiersin.org
- Frontiers | Antigen Cross-Presentation by Macrophagesfrontiersin.org
- Frontiers | The Role of NK Cells and Innate Lymphoid Cells in Brain Cancerfrontiersin.org
- Frontiers | Organic Molecules in Interstellar Space: Latest Advancesfrontiersin.org
- Frontiers | Principles and Practice of Explainable Machine Learningfrontiersin.org
- Frontiers | Inflammation: Bridging Age, Menopause and APOEε4 Genotype to Alzheimer’s Diseasefrontiersin.org
- AlphaProteo generates novel proteins for biology and health research — Google DeepMinddeepmind.google
- Frontiers | Deep Learning Driven Drug Discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2frontiersin.org
- Frontiers | A Bayesian model for chronic painfrontiersin.org
- Frontiers | Challenges for Therapeutic Applications of Opsin-Based Optogenetic Tools in Humansfrontiersin.org
- A primer on machine learning in antibody engineeringabhishaike.com
- the drug landscapegenome-browser-eight.vercel.app